International audienceMycobacterium abscessus is difficult to eradicate. At the Montpellier CF Center, we prescribed liposomal amikacin for inhalation to 5 patients with M abscessus infection. The 3 patients who completed the treatment did not have any respiratory exacerbation, showed negative cultures for M abscessus in their sputum, and stabilized their spirometric functions
Rationale: Treatment of pulmonary nontuberculous mycobacteria, especially Mycobacterium abscessus, r...
We examined the therapeutic effects of free and liposome-encapsulated amikacin on Mycobacterium aviu...
Abstract Background In multidrug regimens, including an intravenous aminoglycoside (e.g. amikacin [A...
International audienceBackground Mycobacterium abscessus infections remain difficult to manage in bo...
Pulmonary infections caused by nontuberculous mycobacteria (NTM) are an increasing problem in indivi...
IntroductionThe prevalence of Mycobacterium avium complex (MAC) is increasing globally. Macrolide-ba...
International audienceBackgroundMycobacterium abscessus (Mabs), a rapidly growing Mycobacterium spec...
Mycobacterium abscessus is the etiological agent of severe pulmonary infections in vulnerable patien...
BACKGROUND Shortcomings of inhaled antibiotic treatments for Pseudomonas aeruginosa infection in ...
The management of difficult-to-treat acute and chronic respiratory infections (infections in cystic ...
The pharmacokinetics and pharmacodynamics of a novel liposomal amikacin for inhalation were evaluate...
Jean-Louis Gaillard*, # for the OMA group++ ABSTRACT: Cystic fibrosis (CF) patients are at particula...
Background: The contemporary guidelines have recommended multiple antimicrobial therapies along with...
Atsuho Morita,1 Ho Namkoong,2 Kazuma Yagi,1 Takanori Asakura,1 Makoto Hosoya,3 Hiromu Tanaka,1 Ho Le...
Rationale: Treatment of pulmonary nontuberculous mycobacteria, especially Mycobacterium abscessus, r...
We examined the therapeutic effects of free and liposome-encapsulated amikacin on Mycobacterium aviu...
Abstract Background In multidrug regimens, including an intravenous aminoglycoside (e.g. amikacin [A...
International audienceBackground Mycobacterium abscessus infections remain difficult to manage in bo...
Pulmonary infections caused by nontuberculous mycobacteria (NTM) are an increasing problem in indivi...
IntroductionThe prevalence of Mycobacterium avium complex (MAC) is increasing globally. Macrolide-ba...
International audienceBackgroundMycobacterium abscessus (Mabs), a rapidly growing Mycobacterium spec...
Mycobacterium abscessus is the etiological agent of severe pulmonary infections in vulnerable patien...
BACKGROUND Shortcomings of inhaled antibiotic treatments for Pseudomonas aeruginosa infection in ...
The management of difficult-to-treat acute and chronic respiratory infections (infections in cystic ...
The pharmacokinetics and pharmacodynamics of a novel liposomal amikacin for inhalation were evaluate...
Jean-Louis Gaillard*, # for the OMA group++ ABSTRACT: Cystic fibrosis (CF) patients are at particula...
Background: The contemporary guidelines have recommended multiple antimicrobial therapies along with...
Atsuho Morita,1 Ho Namkoong,2 Kazuma Yagi,1 Takanori Asakura,1 Makoto Hosoya,3 Hiromu Tanaka,1 Ho Le...
Rationale: Treatment of pulmonary nontuberculous mycobacteria, especially Mycobacterium abscessus, r...
We examined the therapeutic effects of free and liposome-encapsulated amikacin on Mycobacterium aviu...
Abstract Background In multidrug regimens, including an intravenous aminoglycoside (e.g. amikacin [A...